Literature DB >> 29806826

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy.

Wei-Jun Wang1, Jeng-Fong Chiou2, Yaoru Huang3.   

Abstract

The prognosis of patients with metastatic cancers has improved in the past decades due to effective chemotherapy and oligometastatic surgery. For inoperable patients, local ablation therapies, such as stereotactic body radiotherapy (SBRT), can provide effective local tumor control with minimal toxicity. Because of its high precision and accuracy, SBRT delivers a higher radiation dose per fraction, is more effective, and targets smaller irradiation volumes than does conventional radiotherapy. In addition, steep dose gradients from target lesions to surrounding normal tissues are achieved using SBRT; thus, SBRT provides more effective tumor control and exhibits fewer side effects than conventional radiotherapy. The use of SBRT is prevalent for treating intracranial lesions (known as stereotactic radiosurgery); however, it is now also used for treating spinal and adrenal metastases. Because of advancements in image-guided assistance and respiratory motion management, several studies have investigated the use of SBRT for treating lung or liver tumors, which move as a patient breathes. The results of these studies have suggested that SBRT favorably controls tumors in the case of moving lesions. Four-dimensional computed tomography (4D-CT) with an abdominal compressor (AC) is clinically convenient for effective respiratory motion management. Because this method is noninvasive and allows free breathing, its use reduces complications. Furthermore, patients consider this method convenient. Moreover, it is considered more efficient than other methods of respiratory motion management by physicians and therapists. The use of 4D-CT with an AC for treating pulmonary lesions has also been widely investigated, and the technique is gaining acceptance for treating hepatic lesions. However, the protocols for using 4D-CT with an AC for treating hepatic lesions are different from those used for treating pulmonary lesions. In this article, we describe a new protocol for SBRT with 4D-CT and an AC for treating liver metastases.

Entities:  

Mesh:

Year:  2018        PMID: 29806826      PMCID: PMC6101159          DOI: 10.3791/57050

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  23 in total

1.  Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial.

Authors:  Marta Scorsetti; Stefano Arcangeli; Angelo Tozzi; Tiziana Comito; Filippo Alongi; Pierina Navarria; Pietro Mancosu; Giacomo Reggiori; Antonella Fogliata; Guido Torzilli; Stefano Tomatis; Luca Cozzi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-20       Impact factor: 7.038

Review 2.  Stereotactic body radiation therapy for liver metastases.

Authors:  Marta Scorsetti; Elena Clerici; Tiziana Comito
Journal:  J Gastrointest Oncol       Date:  2014-06

3.  Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases.

Authors:  Benjamin D Goodman; Edward M Mannina; Sandra K Althouse; Mary A Maluccio; Higinia R Cárdenes
Journal:  Pract Radiat Oncol       Date:  2015-10-23

4.  Liver metastases and SBRT: A new paradigm?

Authors:  Tiziana Comito; Elena Clerici; Angelo Tozzi; Giuseppe D'Agostino
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-06

Review 5.  Oligometastases revisited.

Authors:  Ralph R Weichselbaum; Samuel Hellman
Journal:  Nat Rev Clin Oncol       Date:  2011-03-22       Impact factor: 66.675

6.  Patient-reported complications from fiducial marker implantation for prostate image-guided radiotherapy.

Authors:  S Gill; J Li; J Thomas; M Bressel; K Thursky; C Styles; K H Tai; G M Duchesne; F Foroudi
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

7.  Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center.

Authors:  Waleed Shady; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Karen T Brown; Anne M Covey; William Alago; Jeremy C Durack; Majid Maybody; Lynn A Brody; Robert H Siegelbaum; Michael I D'Angelica; William R Jarnagin; Stephen B Solomon; Nancy E Kemeny; Constantinos T Sofocleous
Journal:  Radiology       Date:  2015-08-12       Impact factor: 11.105

8.  Verification of planning target volume settings in volumetric modulated arc therapy for stereotactic body radiation therapy by using in-treatment 4-dimensional cone beam computed tomography.

Authors:  Wataru Takahashi; Hideomi Yamashita; Satoshi Kida; Yoshitaka Masutani; Akira Sakumi; Kuni Ohtomo; Keiichi Nakagawa; Akihiro Haga
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-04-05       Impact factor: 7.038

9.  Clinical parameters for predicting radiation-induced liver disease after intrahepatic reirradiation for hepatocellular carcinoma.

Authors:  Yaoru Huang; Shang-Wen Chen; Ching-Chao Fan; Lai-Lei Ting; Chia-Chun Kuo; Jeng-Fong Chiou
Journal:  Radiat Oncol       Date:  2016-07-02       Impact factor: 3.481

10.  Evaluation of dosimetric misrepresentations from 3D conventional planning of liver SBRT using 4D deformable dose integration.

Authors:  Unjin A Yeo; Michael L Taylor; Jeremy R Supple; Shankar Siva; Tomas Kron; Daniel Pham; Rick D Franich
Journal:  J Appl Clin Med Phys       Date:  2014-11-08       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.